title: Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer.
abstract: OBJECTIVE
  This study was performed to assess the efficacy and safety of weekly paclitaxel and cisplatin combination chemotherapy in patients with advanced or recurrent gastric cancer.
  
  
  METHODS
  Patients with advanced or recurrent gastric cancer were required to have ECOG performance status of 0 to 2, to be over 20 years of age, and to have adequate organ function. Paclitaxel 80 mg/m2 was administered intravenous over 1.5 h, followed by cisplatin 25 mg/m2 on day 1, 8 and 15 every 4 weeks.
  
  
  RESULTS
  All of the 52 patients enrolled, 49 patients were eligible. One patient had complete response. Nineteen had partial response, 13 had stable disease, 8 had progressive disease and 8 had not been evaluated. The median progression-free survival time was 166.5 days and median survival time was 323 days. The most common grade 3 to 4 hematological toxicies were leucopenia (14.3%), neutropenia (32.7%), and anemia (16.3%). The most common grade 3 non-hematological toxicities included anorexia (6.1%), nausea (4.1%), vomiting (2.0%) and fatigue (2.0%). No grade 4 non-hematological toxicities were reported.
  
  
  CONCLUSIONS
  Combination chemotherapy of weekly paclitaxel and cisplatin was highly active and well tolerated in patients with advanced or recurrent gastric cancer.
authors.affiliation: Department of surgery 1, University of Occupational and Environmental Health, Iseigaoka, Yahatanishi-ku, Kitakyushu-shi, 807-8555, Japan. n-nagata@med.uoeh-u.ac.jp
authors.forename: Naoki
authors.initials: N
authors.lastname: Nagata
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kimura
authors.forename: Naoki
authors.initials: N
authors.lastname: Hirabayashi
authors.forename: Akira
authors.initials: A
authors.lastname: Tuburaya
authors.forename: Teruo
authors.initials: T
authors.lastname: Murata
authors.forename: Ken
authors.initials: K
authors.lastname: Kondo
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Fukuda
authors.forename: Michiya
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Yumi
authors.initials: Y
authors.lastname: Miyashita
authors.forename: Akimasa
authors.initials: A
authors.lastname: Nakao
authors.forename: Junichi
authors.initials: J
authors.lastname: Sakamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy*
chemical_list: D017239:Paclitaxel; D002945:Cisplatin